Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Therapy

Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies

Leukemia volume 14, pages 2052–2058 (2000)Cite this article

Abstract

Twenty-nine consecutive patients with high-risk hematological malignancy aged from 3 to 58 years underwent an unmanipulated graft from an HLA-identical sibling after an irradiation-free preparative regimen consisting of idarubicin (IDA), 21 mg/m2/day administered by continuous infusion on days −12 and −11, followed by busulphan (BU), 4 mg/kg/day orally from day −7 to −4, and cyclophosphamide (CY), 60 mg/kg/day intravenously on days −3 and −2 (IDA-BUCY2). Most clinically relevant extra-hematological regimen-related toxicities consisted of stomatitis observed in all subjects and hemorrhagic cystitis occurred in five cases (17%) within 100 days after transplant. Six patients (21%) developed a grade 2 acute graft-versus-host disease (GVHD) and three (10%) a grade 3 or 4; extensive chronic GVHD was assessed in nine of 22 (41%) evaluable patients. So far, 12 patients have died and 17 are alive, 16 of whom disease-free, 5–41 months after transplant (median, 15 months). The causes of death were related to GVHD in three patients, to sepsis in one and to disease recurrence in the remaining eight. At present, only one of nine relapsed patients is alive. For all patients the actuarial probability of survival (OS) at 1 and 2 years ± standard error (s.e.) was 63 ± 9% and 52 ± 10%, respectively. The actuarial probabilities of disease-free survival (DFS), relapse and transplant-related mortality (TRM) at both 1 and 2 years ± s.e. were 53 ± 9%, 35 ± 9% and 16 ± 7%, respectively. These results are encouraging but not substantially different from those obtained in 28 patients with malignancy in advanced phase transplanted after the standard BUCY2 regimen, who had an actuarial probability of OS, DFS, relapse and TRM projected at 10 years ± s.e. of 54 ± 10%, 57 ± 9%, 36 ± 9% and 11 ± 6%, respectively. Although the retrospective comparison between the two groups does not seem to show any advantage in the use of the IDA intensified regimen, only a prospective randomized trial could answer this question.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Thomas ED . Marrow transplantation for malignant disease (Karnofsky Memorial Lecture) J Clin Oncol 1983 1: 517–531

    Article  CAS  Google Scholar 

  2. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Effenbein GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart RK, Yeager AM . Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulphan and cyclophosphamide New Engl J Med 1983 309: 1347–1353

    Article  CAS  Google Scholar 

  3. Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen Blood 1987 70: 1382–1388

    Article  CAS  Google Scholar 

  4. Blume KG, Kopecky KJ, Henslee-Downey JP, Forman SJ, Stiff PJ, LeMaistre CF, Appelbaum FR . A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group Study Blood 1993 81: 2187–2193

    Article  CAS  Google Scholar 

  5. Ringdèn O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallarfors B, Ljungman P, Mellander L, Jacobsen N for the Nordic Bone Marrow Transplantation Group . A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group Blood 1994 83: 2723–2730

    Article  Google Scholar 

  6. Ringdèn O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R, Sierra J, Gorin C for the Acute Leukaemia Working Party of the EBMT . A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia Br J Haematol 1996 93: 637–645

    Article  Google Scholar 

  7. Linch MHE, Petersen FB, Appelbaum FR, Bensinger WI, Clift RA, Storb R, Sanders JE, Hansen JA, Buckner CD . Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies Bone Marrow Transplant 1995 15: 59–64

    Google Scholar 

  8. Demirer T, Buckner CD, Appelbaum FR, Lambert K, Bensinger WI, Clift R, Storb R, Slattery JT . Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels Bone Marrow Transplant 1996 17: 341–346

    CAS  PubMed  Google Scholar 

  9. Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N . Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia Bone Marrow Transplant 1998 21: 1079–1083

    Article  CAS  Google Scholar 

  10. Przepiorka D, Ippoliti C, Giralt S, Van Beisen K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M, Estey E, Andreeff M, Champlin R . A phase I–II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation Bone Marrow Transplant 1994 14: 449–453

    CAS  PubMed  Google Scholar 

  11. Carpenter PA, Marshall GM, Giri N, Vowels MR, Russell SJ . Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan Bone Marrow Transplant 1996 18: 489–494

    CAS  PubMed  Google Scholar 

  12. Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG, Kumar PP, Warkentin PI, Gordon BG, Bierman PJ, Coccia PF, Armitage JO . Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy Bone Marrow Transplant 1991 8: 489–495

    CAS  PubMed  Google Scholar 

  13. Raemaekers J, De Witte T, Schattenberg A, Van Der Lely N . Prevention of leukemic relapse after transplantation with lymphocyte depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracycline Bone Marrow Transplant 1989 4: 167–171

    CAS  PubMed  Google Scholar 

  14. Muus P, De Witte T, Schattenberg A, Donnely P, Hoogenhout J . Intensification of the conditioning regimen for allogeneic bone marrow transplantation in recipients of T-cell depleted graft by the addition of anthracyclines Leuk Lymphoma 1992 7: 1–6

    Article  Google Scholar 

  15. Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E, De Witte T . Idarubicin-related side effects in recipients of T-cell depleted allogeneic bone marrow transplants are schedule dependent Semin Oncol 1993 20: 47–52

    CAS  PubMed  Google Scholar 

  16. Schaap N, Schattenberg A, Bar B, Preijers F, Geurts Van Kessel A, Van Der Maazen R, De Boo T, De Witte T . Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen Br J Haematol 1997 98: 750–759

    Article  CAS  Google Scholar 

  17. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304

    Article  CAS  Google Scholar 

  18. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED . Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients Am J Med 1980 69: 204–217

    Article  CAS  Google Scholar 

  19. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED . Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    Article  CAS  Google Scholar 

  20. Kaplan EL, Meier P . Non parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  21. Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R . Veno-occlusive disease of the liver following bone marrow transplantation Transplantation 1987 44: 778–783

    Article  CAS  Google Scholar 

  22. Berman E, McBride M . Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug resistant leukemia cells Blood 1992 79: 3267–3276

    Article  CAS  Google Scholar 

  23. Donnelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, DePauw BE . A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients Bone Marrow Transplant 1992 9: 409–413

    CAS  PubMed  Google Scholar 

  24. Sencer SF, Haake RJ, Weisdorf DJ . Hemorrhagic cystitis after bone marrow transplantation Transplantation 1993 56: 875–879

    Article  CAS  Google Scholar 

  25. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD . Transplantation of peripheral blood stem cells mobilised by recombinant human granulocyte colony stimulating factor Blood 1995 85: 1655–1658

    Article  CAS  Google Scholar 

  26. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, Lilleby K, Rowley S, Sanders J, Storb R, Buckner CD . Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation Blood 1996 88: 2794–2800

    Article  CAS  Google Scholar 

  27. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F . Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system Blood 1996 88: 1013–1018

    Article  CAS  Google Scholar 

  28. Abraham R, Szer J, Bardy P, Grigg AP . Early cyclosporine taper in high risk sibling allogeneic bone marrow transplants Bone Marrow Transplant 1997 20: 773–777

    Article  CAS  Google Scholar 

  29. Ringdèn O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation . Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis Bone Marrow Transplant 1996 18: 921–929

    PubMed  Google Scholar 

  30. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R . Mini-allografts: ongoing trials in humans Bone Marrow Transplant 2000 25: 345–350

    Article  CAS  Google Scholar 

  31. Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S, Schwarer AP, Hughes T, Herrmann R, Gibson J, Arthur C, Matthews J . Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukemia Br J Haematol 1999 107: 409–418

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Esterina Livesi for her invaluable support and all the nursing staff. This work was supported in part by grants from the ROMAIL (Associazione Italiana contro le Leucemie-Roma).

Author information

Authors and Affiliations

  1. Dipartimento di Biotecnologie Cellulari ed Ematologia, Università ‘La Sapienza’, Roma, Italy

    A Mengarelli, AP Iori, C Guglielmi, MP Perrone, M Gozzer, C Girmenia, G Cimino, AM Testi, R Ricci, L De Felice, G Girelli, F Mandelli & W Arcese

Authors
  1. A Mengarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. AP Iori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Guglielmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. MP Perrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Gozzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Girmenia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Cimino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. AM Testi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Ricci
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L De Felice
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G Girelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F Mandelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. W Arcese
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mengarelli, A., Iori, A., Guglielmi, C. et al. Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. Leukemia 14, 2052–2058 (2000). https://doi.org/10.1038/sj.leu.2401947

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401947

Keywords

This article is cited by

Search

Advanced search

Quick links